Emerging data suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may offer a promising development for body loss . Early clinical tests https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026